Plain-English translation of NCT06064864 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing Remsima, a medication used to treat Crohn's disease. Researchers want to learn whether patients who improve on the injection form of this medication (given under the skin every 2 weeks) can safely switch to or stay on that form, or whether they should switch back to the intravenous form (given through a vein every 8 weeks). The goal is to help doctors choose the best delivery method for each patient.
The injectable form of this medication was recently approved in Korea, but doctors don't yet have enough real-world information about whether it works as well as the intravenous form, or whether patients can safely switch between the two. This trial will provide that information.
You likely qualify if…
You likely don't qualify if…
You will start by receiving the medication through a vein at weeks 0 and 2, then switch to injections under the skin every 2 weeks starting at week 6. At week 30, your response will be evaluated. If you've improved, you'll be randomly assigned to either continue the injections or switch back to the intravenous form. If you haven't improved, you'll receive a higher dose of the intravenous medication. The study continues until week 54, with regular clinic visits and blood tests to monitor how well the treatment is working and whether you're experiencing any side effects.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
South Korea